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used data from the EuroSC study, a longitudinal cohort of 1208 patients with schizo-
phrenia followed for 2 years. Every 6 months, the collected information included 
QoL-Interview, from which the Global Satisfaction Score (GLS) and the frequency 
of social contacts score were derived, and the Positive And Negative Symptoms 
Scale (PANSS), from which EW score was derived. After bivariate and correlation 
analyses, we tested whether few social contacts at baseline would predict greater 
EW and lower GLS after 2 years when adjusted on baseline level. Finally, random-
effects regression analyses were performed to test the longitudinal effect of social 
contact, adjusting on potential confounding factors. Results: Bivariate and cor-
relation analyses established a link between frequency of social contact and both 
EW score (-0.24, p< 0.001) and negative factor scale (-0.30, p< 0.0001) at each time 
point. Few social contacts at baseline were associated with greater EW (p= 0.013) 
and worse negative factor score (p= 0.009), when compared to baseline. A trend for 
prediction of better QoL was also found, although not reaching significance. Random 
effects regressions confirmed the significant impact of social contacts over time on 
EW (p< 0.0001), negative factor score (p< 0.0001) and QoL (p< 0.001). ConClusions: 
Given consistent effects of social contacts on reduction of negative symptoms and 
improvement of QoL in schizophrenic patients, social contacts should be used as a 
therapeutic tool. A higher frequency of social contacts could be obtained by regular 
therapeutic groups offered to these patients.
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objeCtives: To examine prescription patterns of drugs for the treatment of attention 
deficit disorders in Japanese children and adolescents. Methods: We conducted a 
cross-sectional survey during October 2013 on outpatients aged 19 years or less in 34 
private mental clinics. Patients who were prescribed at least one drug for the treat-
ment of attention deficit disorders were analyzed in this report. Data were extracted 
on gender, age, principal psychiatric diagnosis (based on ICD-10), and types and 
doses of psychotropic drugs. Results: The samples consisted of 286 males and 51 
females. The average age (standard deviation) was 11.6 years (3.1). The mean length 
of psychiatric treatment was 21.3 months (24.0). The most frequent principal diag-
nostic category was “behavioral and emotional disorders with onset usually occurring 
in childhood and adolescence” (F9; n= 237), followed by “disorders of psychological 
development” (F8; n= 99), and “mental retardation” (F7; n= 1). Of 337 samples, 247 
(73.2%) were prescribedOROS methylphenidate (OROS-MPH), a psycho-stimulant, 
while 141 (41.8%) received atomoxetine (ATMX), a selective noradrenalin reuptake 
inhibitor. OROS-MPH/ATMX combination therapy was administered to 51 (15.1%) of 
337 patients. Antipsychotics were concurrently prescribed in 80 (23.7%) patients. Mood 
stabilizers were co-prescribed in 20 (5.9%) cases. Antidepressants were co-prescribed 
in 19 (5.6%) patients. Anxiolytics/hypnotics were concurrently prescribed in 13 (3.9%) 
patients. ConClusions: In Japan, nearly one-sixth of the outpatients with attention 
deficit disorders received OROS-MPH/ATMX combination therapy.
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objeCtives: Prescribing for adult psychiatric patients is often highly complex 
due to the nature of psychiatric conditions, but also due to somatic comorbid-
ity. Therefore, the aim of this study was to identify prevalence and types of 
potential inappropriate prescribing (PIP), asses the severity of potential clinical 
consequences and identify possible predictive factors of PIP. Methods: The study 
was designed as a prospective study of PIP using medication reviews. 
Patients who were admitted during a 4 month period (August 2013 - November 
2013) to a psychiatric university hospital were included (n= 219). The medi-
cation reviews, including an assessment of potential severity, were carried 
out by clinical pharmacologists after admission and after the attending physi-
cian had seen the patient. Frequencies and categories of PIP were analyzed in 
absolute numbers and as percentages. Severity of PIP was assessed using four 
categories. Logistic regression analysis was used to identify possible predic-
tive factors of PIP. Results: The proportion of patients with one or more PIPs 
was 123/219 (56%). “Interaction between drugs” was the most common category 
for potentially serious and potentially fatal PIPs with 49/123 (40%) and 32/45 (71%), 
respectively. Of 32 identified potentially fatal drug-drug interactions, 15/32 (47%) 
involved two or more antipsychotic drugs and 12/32 (37%) involved antipsychotic 
drugs in combination with antidepressants. The remaining 5/32 (16%) potentially 
fatal drug-drug interactions involved propranolol, erythromycin, simvastatin 
and promethazine. After adjusting for age, gender, alcohol/substance abuse, 
number of prescriptions, number of somatic diagnoses and level of kidney 
function, only polypharmacy (> 5 prescriptions) increased the odds for a PIP 
significantly; OR= 4,82 (95%CI: 2.33-9.98), p< 0.0001. ConClusions: PIP is 
frequent and might have serious or fatal consequences. Special attention should be 
given to drug-drug interactions involving antipsychotics and antidepressants but 
also somatic medications and polypharmacy threatens medication safety. There 
is a pressing need to improve the quality in prescribing for psychiatric patients.
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from a common Normal distribution of treatment effects with an overall SSRI class 
effect mean, and between treatment within class heterogeneity. Results: There 
were 55 eligible studies identified in the systematic review. The intervention with 
the greatest decrease in YBOCS was behavioural therapy (“exposure and response 
prevention”) showing a decrease of 13.86 (CrI 9.34 to 18.31). The second and third 
greatest decrease was cognitive therapy (12.80 CrI 7.39 to 18.18) and behavioural 
therapy plus clomipramine (12.47 CrI 5.80 to 19.08) respectively. The SSRI class effect 
showed a relative decrease in mean YBOCS of 2.89 (CrI 1.05 to 4.71) compared to 
pharmacological placebo. The results of the individual SSRIs ranged from a decrease 
of 2.49 (sertraline) to 3.10 (fluvoxamine). ConClusions: This analysis showed a 
combination of behavioural therapy plus clomipramine has the greatest decrease 
in YBOCS. There is little evidence to show a difference between SSRIs.
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Or an atyPical anti-PsycHOtic (aaP) used tO augMent a selective 
serOtOnin reuPtake inHibitOr (ssri) in treatMent resistant 
dePressiOn (trd)
Edwards S.J., Wakefield V., Nherera L., Trevor N.
BMJ, London, UK
objeCtives: To estimate the clinical effectiveness of augmentation of SSRI antide-
pressant therapy with either lithium or an AAP in TRD, defined as failure to respond 
to two or more antidepressants in the current episode of depression. Methods: 
Systematic review of CENTRAL, EMBASE, MEDLINE, and PsycINFO was completed 
in August 2011. Additional data were obtained from manufacturers. Studies were 
assessed for quality using the Cochrane Risk of Bias Tool. Pairwise meta-analysis 
and mixed treatment comparison (MTC) were undertaken based on intention-to-
treat analyses. Results: Of the 3,721 papers found in the literature search, 12 
randomised controlled trials (RCTs) were identified; 10 (SSRI + AAP vs SSRI + pla-
cebo/no treatment); 1 (SSRI + AAP vs SSRI + lithium); 1 (SSRI + lithium vs SSRI + 
placebo). The RCTs included in the primary analyses used fluoxetine as the SSRI and 
olanzapine as the AAP. Results of the MTC showed a non-significant trend in favour 
of lithium augmentation for response [lithium odds ratio (OR) 1.29; 95% credible 
interval (95% CrI): 0.11 to 5.32], mean change in Montgomery-Åsberg Depression 
Rating Scale (MADRS) score from baseline (mean difference -1.47; 95% CrI: -9.10 to 
6.41) and all-cause withdrawals (OR 0.74; 95% CrI: 0.10 to 2.66). ConClusions: In 
patients with TRD, there is a lack of direct evidence comparing the clinical effective-
ness of augmenting an SSRI with an AAP compared with augmenting with lithium. 
Augmentation of SSRIs with lithium or AAP is likely to be beneficial in people with 
TRD. The limited evidence indicates no statistically significant difference between 
the two augmentation strategies.
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objeCtives: Many patients with schizophrenia and bipolar disorder have 
impaired insight and low medication adherence. The aim of this post-hoc anal-
ysis is to explore the relationship between insight and medication adherence 
and their impact on the outcomes of patients with schizophrenia or bipolar 
disorder. Methods: We included 903 patients with schizophrenia or bipolar dis-
order who participated in an observational study conducted in Europe on the out-
comes of patients treated with two oral formulations of olanzapine over a 1-year 
period. Evaluations included Clinical Global Impression (CGI), Global Assessment 
of Functioning (GAF), insight (Scale to Assess Unawareness of Mental Disorder, 
SUMD), non-adherence (Medication Adherence Rating Scale, MARS), and therapeutic 
alliance (Working Alliance Inventory, WAI). Correlations between variables were 
assessed by Spearman Correlation Coefficient (SCC). A path analysis was used to 
understand the relationship between insight, adherence, therapeutic alliance and 
outcomes. Results: 67.8% of patients had schizophrenia. GAF score was higher 
in bipolar vs schizophrenia patients (mean (SD) 58.4 (15.6) vs 51.9 (15.7), p< 0.001). 
Medication adherence was also higher in bipolar patients (mean MARS score (SD) 6.5 
(2.8) vs 5.8 (2.7); p< 0.001). Patients with schizophrenia had lower insight (i.e. SUMD 
item 1, unawareness of mental disorder, mean (SD) of 2.5 (1.3) in schizophrenia vs 
1.9 (1.2) in bipolar, p < 0.001). Better insight was associated with higher adherence 
(SCC, ranging from 0.39 to 0.49 for the three SUMD general items, p< 0.0001 in all 
cases) Higher insight was related to a stronger therapeutic alliance (SCC ranging 
from 0.38 to 0.48, p< 0.0001). The path analysis revealed a positive impact of insight 
on adherence and alliance and that stronger alliance was related to lower clinical 
severity (lower CGI score). ConClusions: Insight and adherence were found to 
be closely related. Insight impacts on the therapeutic alliance with mental health 
professionals. These factors are associated to treatment outcomes.
PMH11
sOcial cOntacts reduce negative syMPtOMs, esPecially eMOtiOnal 
witHdrawal in Patients witH scHizOPHrenia
Millier A.1, Siegrist K.2, Amri I.3, Toumi M.4, Aballéa S.1
1Creativ-Ceutical, Paris, France, 2Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, 
3Creativ-Ceutical, Tunis, Tunisia, 4University of Marseille, Marseille, France
objeCtives: In schizophrenia, negative symptoms - especially emotional with-
drawal (EW) - represent an important dimension, and are associated to a significant 
burden. Social contacts are likely to reduce negative symptoms and ameliorate 
quality of life (QoL) over time. Our objective was to test whether this hypothesis was 
verified in a large cohort of European patients with schizophrenia. Methods: We 
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objeCtives: Buprenorphine/naloxone (BUP/NAL) combination is a well known 
treatment for opioid dependence. As a chronic relapsing disorder, some patients 
alternate between periods of on treatment and off treatment. The aim of this 
study was to compare health care resource utilization and costs between these 
patients and patients treated continuously. Methods: Statistical analyses were 
conducted on a Medicaid insurance claims database (TruvenHealth MarketScan® 
Medicaid) from January 2007 to June 2012. Patients with at least two treatment 
episodes in the first year after the initial filled prescription were identified. The 
end of a treatment episode was defined as a period of 60 days with no filled BUP/
NAL prescriptions following the theoretical end of the last filled prescription. An 
ordered logistic regression model was used to analyze the impact of initial treat-
ment episode duration on the number of new episodes in the year following the 
end of the first episode. Health care resource utilization and related costs during 
the first year after initiation were compared between the two groups. Results: 
2,223 patients were included in the analysis. During the first year, 86% of patients 
had only one treatment episode, 13% had two and 1% had three. Compared to 
patients who remained in treatment continuously over 12 months, the multiple 
treatment episode group had lower medication costs (-$2,877) but higher psychi-
atric inpatient costs (+$720), non-psychiatric inpatient costs (+$2001) and emer-
gency room costs (+430) over 12 months. Total health care costs over 12 months 
were higher among multiple treatment episode patients ($16,583 vs. $15.123, 
p= 0.0004). ConClusions: Despite lower medication costs, total health care costs 
over 12 months were higher among patients with multiple treatment episodes 
compared to patients treated continuously.
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objeCtives: To compare the treatment cost of paliperidone palmitate (PP) versus 
risperidone long acting (R-LA), both indicated for the treatment of schizophrenia in 
Brazil. Methods: In Brazil, both (PP and R-LA) long acting 2nd generation antipsy-
chotics are approved for the treatment of schizophrenia. Published literature shows 
no difference in safety and efficacy between them; therefore, a cost-minimization 
analysis was performed. Yearly treatment costs were calculated for an average dose 
of 37,5 mg per patient in the case of R-LA and 75 mg in the case of PP. The two initial 
treatment doses were considered: for PP, 150 mg on the 1st day and 100 mg on the 
8th day, and for R-LA 21 days oral supplementation with 3 mg of risperidone, accord-
ing to dosing intervals defined in the product label. Prices were gathered from the 
official price list (CMED – Apr’14). Results: PP has the lowest cost of treatment, 
at R$ 12,739 per patient in the 1st year – against R-LA R$ 18,165 – and R$ 11,359 in 
the 2nd year (R-LA has R$ 17,971). Treatment with PP compared to R-LA may bring 
important savings to the payers (HMOs or Government), with potential to reduce 
the cost of treatment by 30% in the 1st year, and 37% in the 2nd year - allowing a 
higher number of patients to be treated at the same budget level. ConClusions: 
Although both molecules, PP and R-LA, have demonstrated similar efficacy, PP offers 
a cost reduction from the perspective of the Brazilian private health care system 
compared to R-LA. In addition, PP offers advantages that can have additional value 
for public and private payers alike such as a monthly injection and no need for 
cold chain. PP can therefore be considered a cost-saving therapeutic option for 
schizophrenia compared to R-LA.
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Approximately 10-20% of individuals with Major Depressive Disorder (MDD) fail to 
respond to antidepressant monotherapy. These individuals with treatment resist-
ant depression (TRD) have been found to be frequent users of health care services, 
thus incurring significantly greater costs than those without TRD. objeCtives: 
To investigate the cost of Treatment-Resistant Depression from a private payer 
perspective in Canada. Methods: An employer-sponsored benefits plan data-
base (2011/2012) was used to define a cohort of Non-TRD and TRD claimants. TRD 
claimants are defined as those on their third antidepressant monotherapy; or 
combination antidepressant therapy; or antidepressant augmented with lithium, 
thyroid hormone or an antipsychotic medication. The cost of prescription medica-
tion utilization, short-term disability (STD), and long-term disability (LTD) benefits 
for employees was calculated (2011 and 2012 $CAN) for both Non-TRD and TRD 
groups. Descriptive statistics were used to characterize the cohort of claimants 
and employees, as well as resources and costs for employees. Results: There 
were 55,324 and 61,028 employee claimants in 2011 and 2012, respectively. 717 
(1.3%) and 798 (1.3%) were TRD claimants; 4,744 (8.6%) and 5,137 (8.4%) were Non-
TRD claimants in 2011 and 2012, respectively. In 2011, the medication costs for 
treating depression was $774 per TRD employee claimant compared to $303 per 
Non-TRD claimant. STD costs were $6,263 for TRD (n= 79) and $5,855 for Non-TRD 
(n= 276). LTD costs were $13,598 for TRD (n= 80) and $12,272 for Non-TRD (n= 119). 
In 2012, the medication costs for treating depression per TRD employee claimant 
was $794 compared to $293 for Non-TRD claimants. STD costs were $7,832 for TRD 
(n= 86) and $4,001 for Non-TRD (n= 248). LTD costs were $13,927 for TRD (n= 89) 
and $12,901 for Non-TRD (n= 121). ConClusions: Claimants identified with TRD 
had higher medication, STD and LTD costs than those with Non-TRD. Limitations 
include lack of diagnostic information for claimants and small sample sizes for 
STD and LTD subgroups.
objeCtives: Major depressive disorder affects approximately 10-15% of the popu-
lation and is associated with significant morbidity and mortality. It is one of the 
leading causes of disability in young adults. A large proportion of the burden can be 
attributed to treatment-resistant depression (TRD). To understand the prevalence 
and disease burden of TRD in Western European countries, the US and Canada, a 
systematic literature search was performed. Methods: OVID, the Cochrane Library 
and the CRD database were used to retrieve TRD publications in English language 
from January 2003-October 2013. In total, 6306 abstracts were identified. Predefined 
selection criteria regarding study design, patient population (age ≥ 12 years; US, 
Canada, Germany, Italy, France, Spain or UK; TRD defined as one treatment failure 
and high symptom severity e. g. MADRS ≥ 31, or an inadequate response to ≥ two 
antidepressants) and outcomes of interest were applied. Results: Only seven stud-
ies included prevalence and/or disease burden data. Five studies provided preva-
lence estimates which adhered to the strict TRD definition used for this review. 
Study design and definition of the patient population were critical in determining 
the prevalence rates, with the lowest rates found in US employer claims databases 
(11-15%), higher rates in commercial health insurance databases (29-31%) and the 
highest rates in a European multicenter study (51-56%). The database studies mainly 
included employed patients thereby likely underestimating the prevalence, whereas 
the European study likely overestimated the prevalence due to a less stringent TRD 
definition. Inconsistent data were reported regarding treatment outcomes, comor-
bidities, hospitalization and work productivity. There was no information on other 
outcomes such as health-related quality of life or functioning. ConClusions: No 
consistent data were found in the literature from January 2003-October 2013 regard-
ing the epidemiology and disease burden of TRD. To determine the prevalence and 
disease burden for TRD, further studies are needed.
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objeCtives: The aim of this study was to estimate the prevalence of metabolic syn-
drome (MS) in patients with schizophrenia according to the presence or absence of 
negative symptoms. Methods: A retrospective, cohort study was conducted using 
electronic medical records from the health provider BSA (Badalona, Spain). All adult 
outpatients with a diagnosis of schizophrenia were followed for 12 months. Two study 
groups were defined by the presence or absence of negative symptoms based on the 
PANSS Marder Negative Symptoms Factor (N1-N4, N6, G7 and G16). MS prevalence was 
estimated using the NCEP ATP III criteria. Descriptive statistics and logistic regres-
sion models were applied. Results: We studied 1,120 patients (mean age: 46.8 ± 
13.8 years; male: 58.4%). One or more negative symptoms were present in 52.5% of 
patients (95%CI: 49.6-55.4%). Dyslipidemia (48.7%), hypertension (38.2%), and diabetes 
mellitus (19.3%) were the most frequent comorbid conditions. Quetiapine, risperidone 
and olanzapine were the most common antipsychotic drugs administered. Patients 
with negative symptoms showed a greater mean number of comorbid conditions than 
patients without this symptomatology (8.5 and 7.0, respectively; p< 0.001). Prevalence 
of MS was 38.6% (CI: 35.7-41.5%), higher among patients with one or more negative 
symptoms (43.9% vs. 34.9%, respectively; p= 0.002). MS was associated with the pres-
ence of negative symptoms, age, and comorbidity (OR= 1.6, 1.2, and 1.2, respectively; 
p< 0.05). ConClusions: Further studies are necessary to elucidate the association 
between the presence of negative symptoms and MS among patients with schizo-
phrenia as well as the underlying mechanisms involved.
Mental HealtH – cost studies
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objeCtives: To quantify the economic burden of schizophrenia relapse in 
Brazil, and to estimate the impact of atypical Long Acting Injectables (LAIs) on 
relapse. Methods: Administrative health service data from a Brazilian public system 
database (DATASUS) were used to estimate the number of relapse patients and related 
resource utilisation. Corresponding data for private system patients were estimated 
based on published literature and by extrapolating DATASUS data. A prevalence-based 
costing with a mixed bottom-up and top-down approach was used to quantify direct 
and indirect costs, disability adjusted life years (DALYS) and their associated monetary 
value. A decision-analytic model was constructed to evaluate the cost effectiveness 
of potentially transferring non-compliant patients from oral antipsychotics to atypi-
cal LAIs. All costs are presented in 2013 Brazilian real. Results: In 2011-12, 88,721 
patients with schizophrenia in Brazil experienced 263,037 episodes of relapse that 
resulted in hospital or outpatient care. The potential avoidable health care cost of 
relapse was R$722.6 million. The estimated additional health care cost per DALY 
avoided was R$5,049 if non-compliant patients could be transferred to atypical LAIs 
to achieve 5% overall utilisation. Reducing relapses would give Brazil potential avoid-
ance of 1,335 DALYs, which corresponds to a saving of R$482.8 million in the stock 
of health capital. ConClusions: The economic burden of schizophrenia relapse in 
Brazil is significant. Brazilian policymakers should provide greater access to LAIs.
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